Zevra 2025 net income hits $83M on $106M revenue

Q4 revenue rose 31% quarter-over-quarter to $34.1M as MIPLYFFA sales reached $87.4M for 2025 and cash stood at $238.9M.

Published on Mar. 9, 2026

Got story updates? Submit your updates here. ›

Zevra Therapeutics, Inc., a commercial-stage company focused on providing therapies for people living with rare disease, reported its financial results for the fourth quarter and full year ended December 31, 2025. The company's lead product, MIPLYFFA (arimoclomol) for the treatment of Niemann-Pick disease type C (NPC), saw strong performance, with $87.4 million in net revenue for 2025 and 52 prescription enrollment forms received in Q4 2025, bringing the total to 161 since product launch. Zevra also reported a net income of $83.2 million, or $1.40 per basic and $1.35 per diluted share, for 2025, compared to a net loss of $105.5 million in 2024.

Why it matters

Zevra's strong financial performance, driven by the success of its lead product MIPLYFFA, highlights the company's ability to execute on its strategic priorities and create value for the rare disease community and its shareholders. The company's relocation to Boston and its focus on executing against multiple near-term growth opportunities in 2026 suggest that Zevra is well-positioned to continue its momentum in the rare disease space.

The details

Zevra reported Q4 2025 revenue of $34.1 million, a 31% increase quarter-over-quarter, with $26.4 million coming from MIPLYFFA net revenue. For the full year 2025, Zevra reported revenue of $106.5 million, including $87.4 million from MIPLYFFA. The company also reported a net income of $83.2 million for 2025, compared to a net loss of $105.5 million in 2024. Zevra's cash, cash equivalents, and securities stood at $238.9 million as of December 31, 2025, which the company believes provides sufficient resources and financial flexibility to execute on its strategic priorities.

  • Zevra received 24 MIPLYFFA prescription enrollment forms for Niemann-Pick disease type C (NPC) during Q4 2025, bringing the total to 52 in 2025 and 161 since product launch.
  • Zevra enrolled eight patients in the event-driven Phase 3 DiSCOVER trial for the treatment of Vascular Ehlers-Danlos Syndrome during Q4 2025, bringing the total number of enrolled patients at year-end to 52, with a total of one confirmed event.

The players

Zevra Therapeutics, Inc.

A commercial-stage company focused on providing therapies for people living with rare disease.

Neil F. McFarlane

Zevra's President and Chief Executive Officer.

MIPLYFFA (arimoclomol)

Zevra's approved therapy for the treatment of Niemann-Pick disease type C (NPC).

Vascular Ehlers-Danlos Syndrome

A rare genetic disorder that affects the connective tissues in the body, for which Zevra is conducting a Phase 3 trial with its investigational candidate celiprolol.

Food and Drug Administration (FDA)

The regulatory agency that approved MIPLYFFA for the treatment of NPC in the United States.

Got photos? Submit your photos here. ›

What they’re saying

“MIPLYFFA is making a meaningful difference for patients with Niemann-Pick disease type C, and its strong, accelerating performance reinforces our confidence in its long-term potential.”

— Neil F. McFarlane, Zevra's President and Chief Executive Officer (Zevra Therapeutics, Inc.)

What’s next

The judge in the case will decide on Tuesday whether or not to allow Walker Reed Quinn out on bail.

The takeaway

This case highlights growing concerns in the community about repeat offenders released on bail, raising questions about bail reform, public safety on SF streets, and if any special laws to govern autonomous vehicles in residential and commercial areas.